Almost no one searching for “Melanotan 1” realizes they are asking about two different things at once. On one side is afamelanotide, marketed as Scenesse — a properly developed, FDA-approved drug with real clinical-trial evidence behind it. On the other is an unapproved injectable sold online as a tanning peptide, borrowing the same name and the same underlying mechanism but none of the standing. They are not the same product, and the whole point of this monograph is to keep them apart. The approved drug is legitimate and narrow; the gray-market vial is unregulated and unproven for what people actually buy it for.
What “Melanotan I” actually is
Melanotan I is a synthetic analog of α-melanocyte-stimulating hormone (α-MSH), the body’s natural pigment signal. It works by activating the melanocortin-1 receptor (MC1R) on pigment cells, which increases production of eumelanin — the same pathway your skin uses to darken in response to sunlight.[1] That is the real, coherent pharmacology, and it is the reason the molecule could be developed into a medicine at all. Where the story splits is in what was done with that mechanism: one version went through clinical trials and regulatory approval, and the other was sold as a shortcut to a tan.
This is also the cleanest way to separate Melanotan I from its more notorious relative. Melanotan II is a broader melanocortin agonist whose reach extends past MC1R into MC4R — the receptor tied to sexual function and appetite — which is why MT-2 produces erections, nausea and a heavier side-effect load that afamelanotide largely does not. We lay that contrast out in full in our Melanotan 1 vs Melanotan 2 comparison, and cover the gray-market tanning product itself in the Melanotan II evidence review. The short version: “1” and “2” are not dose levels of one peptide — they are different molecules with different receptor footprints and opposite regulatory fates.
The legitimate side: afamelanotide (Scenesse) is a real, approved drug
Afamelanotide is not a research-peptide curiosity. It is an FDA-approved prescription medicine, supplied as a 16 mg bioresorbable subcutaneous implant that a trained clinician places under the skin roughly every two months.[1] Its approved indication is precise and narrow: to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP) — a rare inherited disorder in which even brief sunlight causes severe, burning skin pain.[1] Note what that indication is not: it is not a cosmetic tanning approval. The pigment increase is a means to an end — light tolerance for people with a painful photosensitivity disease.
That approval rests on genuine randomized evidence. In the pivotal trials published in the New England Journal of Medicine, afamelanotide implants significantly increased the pain-free time EPP patients could spend in sunlight and improved quality-of-life measures versus placebo.[2]The benefit has held up outside the trial setting, too: a large clinical-practice cohort published in JAMA Dermatology found that afamelanotide was associated with more time spent outdoors, fewer and less severe phototoxic reactions, and improved quality of life over years of real-world use.[3]This is what a legitimately developed melanocortin drug looks like: a defined patient population, a controlled formulation, medical supervision, and evidence to match.
The gray-market side: the injectable “Melanotan 1” sold for tanning
Here is where the honesty has to be blunt. The vials sold online as “Melanotan 1” for cosmetic tanning are not the approved afamelanotide implant. They are unregulated “research” powder or solution, of unverified identity, concentration and purity, injected by the user with no medical oversight and no label indication behind them. Using an α-MSH analog to tan is off-label and unstudied as a cosmetic practice: there is no approved formulation, no established cosmetic dose, and no body of safety data supporting recreational use. A peer-reviewed dermatology review of the “risks of unregulated use of α-MSH analogues” makes the point directly — these agents have genuine biological activity, they are bought online and self-injected outside any medical system, and that combination of real pharmacology plus zero oversight is exactly what makes them hazardous.[4]
The most important safety concern is specific to what these molecules do. Because they ramp up melanocyte activity, the relevant question is what happens to moles. Clinicians have documented visible changes in existing moles linked to use of unlicensed “sun tan jab” melanocortin injections — darkening and change that can confound the visual surveillance dermatologists rely on to catch melanoma early.[5] That is a real problem for any pigment-driving agent used cosmetically and unmonitored: a convincing tan and a melanoma-surveillance headache can be two faces of the same pharmacology. Layered on top are the generic hazards of injecting an unverified gray-market product — gastrointestinal upset, flushing, blood-pressure and cardiovascular effects, and contamination risk — without knowing what is actually in the vial.[4]
How Melanotan I compares to its relatives
Two contrasts are worth holding in mind. First, against Melanotan II: afamelanotide is the comparatively MC1R-weighted, pigment-focused molecule that became a controlled drug, while MT-2 is the broader, MC4R-reaching agonist that stayed gray-market and carries the heavier documented harm record, including priapism and more pronounced systemic effects. Second, against the approved libido drug bremelanotide (PT-141): that molecule was developed to exploit the central melanocortin (MC4R) pathway for sexual dysfunction, whereas afamelanotide’s value is in the peripheral MC1R pigment pathway. All three descend from the same melanocortin family, but they were built for — and approved (or not) for — very different jobs. Understanding which receptor each one leans on is the single best way to keep them straight.
The honest bottom line
Melanotan I is the rare case where the honest verdict has to be split down the middle. As afamelanotide (Scenesse), it is a legitimate, FDA-approved melanocortin-1 receptor agonist with Phase 3 randomized evidence and real-world confirmation — but only for a narrow purpose: reducing phototoxic light-pain in people with erythropoietic protoporphyria, delivered as a clinician-placed implant under medical supervision. As the injectable “Melanotan 1”sold online for a tan, it is something else entirely: an unregulated, unverified product whose cosmetic use is off-label, unstudied, and attached to genuine concerns about moles and melanoma surveillance. If you came here to decide whether to buy a tanning peptide, the honest answer is that the approved drug is not what is for sale, and what is for sale is not the approved drug. To see the full family picture, read our Melanotan 1 vs Melanotan 2 comparison and the Melanotan II evidence review, then place it against the wider catalog in our peptide evidence matrix.
This article is descriptive scientific and regulatory information, not medical advice and not a how-to. Afamelanotide (Scenesse) is a prescription medicine indicated only for erythropoietic protoporphyria and is administered by trained clinicians; nothing here is guidance to obtain or use it, or the unregulated injectable sold under the “Melanotan 1” name, for any cosmetic purpose. Discuss any concern about photosensitivity, moles, or skin cancer risk with a licensed clinician.
